Venkat Reddy Mali

20120270842, Oct 25, 2012

Apr 27, 2012

13/458452

K. RAJA REDDY - San Diego CA, US
Jeff Stebbins - San Diego CA, US
Serge H. Boyer - San Diego CA, US
Mark D. Erion - Del Mar CA, US
Scott J. Hecker - Del Mar CA, US
Nicholas Brian Raffaele - San Diego CA, US
Brett C. Bookser - San Diego CA, US
Venkat Reddy Mali - Cupertino CA, US

Metabasis Therapeutics, Inc. - La Jolla CA

A61K 31/66
A61K 31/675
C07F 9/02
C07F 9/30
A61P 3/06
A61K 31/661
C07D 473/32
A61K 31/52
A61P 3/04
C07D 498/04
C07F 9/06

514 81, 544105, 558190, 514115, 548119, 514 92, 544244, 558 86, 514110, 544277, 5142634

The invention pertains to use of DGAT-1 inhibitors to treat and/or prevent overweight, obesity and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease. Compounds and compositions suitable for use in the disclosed methods are also provided.

20130165423, Jun 27, 2013

Nov 30, 2012

13/691589

Yandong Li - San Jose CA, US
Venkat Reddy Mali - Cupertino CA, US
Jay Powers - Pacifica CA, US
Ju Yang - Palo Alto CA, US

ChemoCentryx, Inc. - Mountain View CA

C07D 401/14
C07D 403/14
C07D 405/14
C07D 401/10
C07D 403/12

51421018, 546194, 514318, 5462734, 514338, 544370, 51425406, 5462757, 544371, 544366, 546187, 514316, 544364, 51425309, 5462684

Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

20130172315, Jul 4, 2013

Nov 30, 2012

13/691571

Junfa Fan - Foster City CA, US
Christorpher W. Lange - El Cerrito CA, US
Manmohan Reddy Leleti - Cupertino CA, US
Yandong Li - San Jose CA, US
Venkat Reddy Mali - Cupertino CA, US
Jeffrey P. MacMahon - San Francisco CA, US
Jay Powers - Pacifica CA, US
Sreenivas Punna - Sunnyvale CA, US
Ju Yang - Palo Alto CA, US

ChemoCentryx, Inc. - Mountain View CA

C07D 401/06
C07D 211/26
C07D 413/06
C07D 417/04
C07D 241/04
C07D 401/04
C07D 405/06
C07D 211/70
C07D 403/06

51421018, 546194, 514318, 546191, 514316, 546234, 514331, 544130, 5142355, 546208, 514326, 544365, 51425313, 544372, 51425401, 544393, 51425503, 544394, 544121, 5142358, 544374, 5142541, 540544, 51421115, 544 582, 5142278

Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

20120214769, Aug 23, 2012

Apr 8, 2011

13/083321

K. Raja Reddy - San Diego CA, US
Paul D. van Poelje - La Jolla CA, US
Robert Huerta Lemus - Escondido CA, US
Thanh Huu Nguyen - Solana Beach CA, US
Matthew P. Grote - Carlsbad CA, US
Qun Dang - San Diego CA, US
Scott J. Hecker - Del Mar CA, US
Venkat Reddy Mali - San Diego CA, US
Mingwei Chen - San Diego CA, US
Zhili Sun - San Diego CA, US
Serge Henri Boyer - San Diego CA, US
Haiqing Li - San Diego CA, US
William Craigo - San Diego CA, US

METABASIS THERAPEUTICS, INC. - La Jolla CA

A61K 31/675
A61K 31/185
C07D 307/81
A61K 31/343
C07D 295/185
A61K 31/4965
C07D 213/75
A61K 31/4418
C07D 405/04
A61K 31/443
C07D 235/30
A61K 31/4184
C07F 9/655
A61K 31/665
C07D 471/04
A61K 31/437
C07F 9/40
A61K 31/662
C07D 295/135
A61K 31/5375
C07D 261/08
A61K 31/42
C07F 9/653
A61P 3/10
A61P 3/08
A61P 1/16
A61P 3/06
A61P 9/10
A61P 3/04
A61P 3/00
C07C 309/15

514 92, 562 44, 514576, 549469, 514469, 544391, 51425501, 546309, 514352, 5462841, 514337, 5483081, 514395, 549220, 514100, 546121, 514300, 558173, 514119, 544159, 5142378, 548247, 514378, 548119

The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

20220280481, Sep 8, 2022

Nov 16, 2021

17/527939

- San Carlos CA, US
Karen EBSWORTH - San Francisco CA, US
Antoni KRASINSKI - Sunnyvale CA, US
Venkat Reddy MALI - Cupertino CA, US
Jeffrey McMAHON - San Francisco CA, US
Rajinder SINGH - Belmont CA, US
Ju YANG - Palo Alto CA, US
Chao YU - Sunnyvale CA, US
Penglie ZHANG - Foster City CA, US

A61K 31/4035
A61P 29/00
A61P 17/06

The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula:

20220194929, Jun 23, 2022

Sep 9, 2021

17/470464

- San Carlos CA, US
Junfa FAN - Palo Alto CA, US
Christopher W. LANGE - Hayward CA, US
Manmohan Reddy LELETI - Dublin CA, US
Yandong LI - San Diego CA, US
Venkat Reddy MALI - Cupertino CA, US
Jeffrey P. McMAHON - San Francisco CA, US
Jay POWERS - Pacifica CA, US
Sreenivas PUNNA - Sunnyvale CA, US
Ju YANG - Palo Alto CA, US

C07D 413/06
C07D 401/04
C07D 403/06
C07D 405/06
C07D 417/04
C07D 211/56
C07D 295/135
C07D 211/62
C07D 401/06
C07D 211/26
C07D 211/70
C07D 241/04
C07D 207/16
C07D 211/34
A61K 31/451
A61K 31/454
A61K 31/4545
A61K 31/495
A61K 31/496
A61K 31/5377

Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

20230115912, Apr 13, 2023

Sep 13, 2022

17/931801

- San Carlos CA, US
Christopher W. LANGE - Hayward CA, US
Viengkham MALATHONG - Mountain View CA, US
Venkat Reddy MALI - Cupertino CA, US
Sreenivas PUNNA - Sunnyvale CA, US
Hiroko TANAKA - Mountain View CA, US
Yibin ZENG - Foster City CA, US
Penglie ZHANG - Foster City CA, US

A61K 31/437
A61P 37/00
A61P 35/00
A61P 9/00

The present disclosure provides, inter alia, Compounds of Formula (I)or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

20230097128, Mar 30, 2023

Aug 16, 2022

17/820179

- San Carlos CA, US
Venkat Reddy MALI - Cupertino CA, US
Rajinder SINGH - Belmont CA, US
Ju YANG - Palo Alto CA, US
Penglie ZHANG - Foster City CA, US

A61K 31/4545
A61K 39/395
A61P 35/00
A61K 31/357
A61K 31/165

The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.